Nektar Therapeutics

Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates
Nektar sells off royalties on its 2 approved drugs for $150M in cash, redoubling focus on I-O candidates
Endpoints
Nektar Therapeutics
Adynovate
Movantik
HealthCare Royalty Partners
Flag link:
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in mice
Fierce Biotech
melanoma
Nektar Therapeutics
bempegaldesleukin
Flag link:
Nektar pulls NDA for pain drug after unanimous AdComm rejection
Nektar pulls NDA for pain drug after unanimous AdComm rejection
Fierce Biotech
Nektar Therapeutics
opioids
FDA
oxycodegol
Flag link:
Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee
Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee
Motley Fool
Nektar Therapeutics
FDA
oxycodegol
painkillers
Flag link:
Nektar shows durability of Opdivo combo in 18-month update
Nektar shows durability of Opdivo combo in 18-month update
Fierce Biotech
Nektar Therapeutics
NKTR-214
Opdivo
Bristol-Myers Squibb
melanoma
clinical trials
Flag link:
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
Motley Fool
SITC
cancer immunotherapy
Autolus Therapeutics
Mirati Therapeutics
Nektar Therapeutics
Flag link:
This Bristol-Partnered Biotech Stock Just Fumbled On A Cancer Study
This Bristol-Partnered Biotech Stock Just Fumbled On A Cancer Study
Investors Business Daily
Bristol-Myers Squibb
Nektar Therapeutics
breast cancer
clinical trials
NKTR-214
Flag link:
Nektar Therapeutics stock drops after results
Nektar Therapeutics stock drops after results
Marketwatch
Nektar Therapeutics
earnings
Flag link:
Nektar takes a hit as the FDA swerves away from opioid reviews — leaving NKTR-181 in limbo
Nektar takes a hit as the FDA swerves away from opioid reviews — leaving NKTR-181 in limbo
Endpoints
Nektar Therapeutics
opioids
NKTR-181
FDA
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo
BioCentury
ASCO 2019
NKTR-214
Nektar Therapeutics
metastatic melanoma
Flag link:
What Is Nektar Therapeutics' New Game Plan?
What Is Nektar Therapeutics' New Game Plan?
Motley Fool
Nektar Therapeutics
spinoffs
NKTR-181
non-opioid pain treatments
Flag link:
Nektar Therapeutics launches Inheris Biopharma
Nektar Therapeutics launches Inheris Biopharma
Pharmaceutical Business Review
Nektar Therapeutics
Inheris Biopharma
CNS
Flag link:
In a change of plans, Nektar spins out its opioid into a new biotech subsidiary as FDA PDUFA date looms
In a change of plans, Nektar spins out its opioid into a new biotech subsidiary as FDA PDUFA date looms
Endpoints
Nektar Therapeutics
spinoffs
NKTR-181
opioids
Inheris Biopharma
Flag link:
Bladder cancer readout sees Nektar shares hit
Bladder cancer readout sees Nektar shares hit
Fierce Biotech
Nektar Therapeutics
bladder cancer
NKTR-214
Opdivo
Bristol-Myers Squibb
Flag link:
Here's Why Nektar Therapeutics Surged Today
Here's Why Nektar Therapeutics Surged Today
Motley Fool
Nektar Therapeutics
JPMHC 2019
NKTR-214
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Flag link:
Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?
Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?
Motley Fool
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-2014
Flag link:
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst
Nektar’s long-acting IL-2 NKTR-214 has 'zero value,' claims analyst
Fierce Biotech
Nektar Therapeutics
NKTR-214
Flag link:

Pages